On September 24, 2024 Araris Biotech AG ("Araris"), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), reported it has entered into an Agreement with Innate Pharma ("Innate") (Press release, Araris Biotech, SEP 24, 2024, View Source [SID1234651284]). Under the agreement, Innate will assign its portfolio of patents related to its ADC transglutaminase conjugation technology to Araris.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to acquire Innate’s portfolio of transglutaminase related patents, as this transaction further positions Araris as a leader in the development of ADCs using transglutaminase conjugation technology," said Dragan Grabulovski, Ph.D., CEO and co-founder of Araris. "We look forward to continuing to develop next-generation sitespecific ADCs and believe this acquisition not only expands our intellectual property portfolio, but also strengthens our competitive edge."

The newly acquired patents encompass a broad range of intellectual property that cover use of bacterial transglutaminase in conjugating various linker-payloads to antibodies.